Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > CRO and EDC Companies Launch Partnership and Deliver Integrated Solutions for Medical Device Companies Conducting Clinical Research

Abstract:
Pleiad Devices Joins OmniComm's CRO Preferred ProgramTM and Chooses the TrialMasterTM Electronic Data Capture (EDC) Solution Exclusively for Clinical Trials

CRO and EDC Companies Launch Partnership and Deliver Integrated Solutions for Medical Device Companies Conducting Clinical Research

FT. LAUDERDALE, FL | Posted on March 12th, 2008

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that after extensive evaluation of the industry's leading EDC systems, Pleiad Devices has chosen OmniComm as its preferred EDC vendor. Pleiad is an international Medical Device Contract Research Organization (CRO) with offices located in Europe and the US. The company's primary focus is providing clinical trial support services for medical device companies. As part of the partnership with OmniComm, Pleiad will take full advantage of the flexible, intuitive and robust EDC solution, TrialMaster, in an upcoming ophthalmology trial.

"Pleiad's clinical research team has years of experience in designing, organizing and managing clinical projects for medical device companies," said Stephen Brandao, Vice President of Business Development for Pleiad Devices. "Over the years, our team has had experience with most of the EDC vendors in the marketplace. TrialMaster is one of the best EDC products that we have seen and we look forward to offering our medical device customers this premier service."

The team of clinical professionals at Pleiad Devices specializes in clinical research support specifically for medical device companies. The company understands the regulatory issues in North America and Europe and provides quality clinical research services that serve regulatory, marketing and reimbursement clinical research needs internationally. Pleiad ensures compliance with all FDA and EU clinical research regulations so that all clinical data meet the regulatory standards of the major medical device markets. The clinical team offers expertise in a wide variety of areas including endovascular surgery, orthopedics, gynecology, tissue ablation, ophthalmology, combination products, drug delivery technologies and nanotechnology.

"Our CRO Preferred Program offers companies like Pleiad a true partner that will deliver the ancillary services that CROs need to be competitive in the evaluation process such as co-marketing and sales support for EDC. We offer the consummate partnership, both comprehensive company support and delivery of a first class EDC product," said Stephen Johnson, Executive Vice President of Business Development, Services and Client Services and Support. "At OmniComm, we are confident that our partnerships with CROs like Pleiad will ensure quality deliverables for the clinical research clients that we serve."

####

About OmniComm Systems, Inc.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

For more information, please click here

Contacts:
Lizanne Kelley
OmniComm Systems, Inc.
954-473-1254 Extension 283

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Nanomedicine

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Announcements

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Alliances/Partnerships/Distributorships

Economics = MC2 -- A portrait of the modern physics startup: Successful companies founded by physicists often break the Silicon Valley model, according to new American Institute of Physics report April 23rd, 2014

Global leader in solar cell manufacturing eyes New York for major expansion outside of Japan: CNSE and Solar Frontier Explore $700 Million Investment, Job Creation in New York State April 22nd, 2014

ASM International Repositions Brand and Introduces New Logo; Looks to Future of Materials Science Innovation: New logo celebrates organization’s history and provides fresh elements for future growth April 21st, 2014

Virus structure inspires novel understanding of onion-like carbon nanoparticles April 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE